OrthoPediatrics Corp. - KIDS STOCK NEWS

OrthoPediatrics Corp. (Nasdaq: KIDS) reported a 96% revenue increase for Q2 2021, reaching $26.7 million compared to $13.6 million in Q2 2020. U.S. revenue rose 79% to $21.7 million, while international revenue surged 243% to $5.0 million. Key drivers included substantial growth in Trauma & Deformity (up 95%), Scoliosis (up 100%), and Sports Medicine (up 106%). Gross profit improved by 103% to $20.4 million, with a profit margin of 76.6%. The company increased its full-year revenue guidance to $97-$101 million, indicating strong momentum despite potential COVID-19 challenges.

OrthoPediatrics Corp. (Nasdaq: KIDS) announces a five-year extension of its partnership with Mighty Oak Medical, prolonging their exclusive distribution of FIREFLY Technology until August 2027. This collaboration has enhanced pediatric surgical outcomes by providing 3D printed, patient-specific navigation guides that minimize intraoperative radiation. The partnership underscores a shared commitment to improving the lives of children facing orthopedic challenges.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced its Diamond sponsorship for the 31^st Annual Baltimore Limb Deformity Course, returning to a live format after a virtual event in 2020. The event will take place from August 4 to 8 in Baltimore, Maryland, where the company will offer registration scholarships to residents and fellows. OrthoPediatrics will also showcase its External Fixation portfolio through hands-on demonstrations and workshops. Newly appointed CEO David Bailey emphasized the event's significance in pediatric orthopedic education.

OrthoPediatrics Corp. (NASDAQ: KIDS) is set to announce its second quarter 2021 financial results on August 5, 2021, prior to market opening. A conference call will follow at 8:00 a.m. ET, providing insights into the financial performance. Interested parties can join via dial-in numbers or online webcast. OrthoPediatrics, established in 2006, focuses exclusively on pediatric orthopedics, offering 36 surgical systems across major categories such as trauma, scoliosis, and sports medicine. The company distributes globally, affecting pediatric orthopedic care.

OrthoPediatrics Corp. (NASDAQ: KIDS) has launched its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis (SCFE) Cannulated Screw system after receiving FDA 510(k) clearance. This innovative system features fully and partially threaded screws designed specifically for pediatric patients, available in 2mm increments. The addition expands OrthoPediatrics' offerings, which now includes screws in multiple sizes to meet the needs of pediatric orthopedic surgeons. This launch reinforces the company's commitment to advancing pediatric orthopedic care.

OrthoPediatrics Corp (Nasdaq: KIDS) announced participation in the 2021 JMP Securities Life Sciences Conference on June 17, 2021. Key executives, including CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl, will engage in a fireside chat at 12:00pm ET. An audio webcast of the event will be available on the company's investor relations website, with a replay accessible for 90 days post-event. OrthoPediatrics specializes in pediatric orthopedics, offering 36 surgical systems across trauma, scoliosis, and sports medicine.

OrthoPediatrics Corp. (Nasdaq: KIDS) has completed a leadership transition, appointing David Bailey as the new Chief Executive Officer, succeeding Mark Throdahl, who will remain as Executive Chairman. Throdahl praised Bailey's experience since joining the company in 2007, expressing confidence in his leadership. Bailey emphasized that the company's strategy will remain unchanged, focusing on executing growth plans and delivering innovative products for pediatric orthopedic surgeons to improve children's lives. The company markets 36 surgical systems across key categories in pediatric orthopedics.

OrthoPediatrics Corp. (Nasdaq: KIDS) has launched its RESPONSE™ Neuromuscular Scoliosis System, marking its 36th surgical system introduction. The system, cleared by the FDA in 2020, targets pediatric patients with neuromuscular scoliosis, developed in collaboration with pediatric orthopedic surgeons. This innovative system integrates with existing RESPONSE Scoliosis offerings and aims to enhance surgical efficiency and patient outcomes. OrthoPediatrics focuses exclusively on pediatric orthopedic solutions, distributing in the U.S. and 45 other countries.

OrthoPediatrics Corp. (NASDAQ: KIDS) has reaffirmed its support for the 2021 Pediatric Orthopaedic Society of North America (POSNA) annual meeting, which saw over 400 participants despite COVID-19 challenges. As a Double Diamond Sponsor, the company contributed to educational symposia and scholarships. The press release highlighted its Scoliosis franchise, particularly the ApiFix technology, designed for less invasive scoliosis correction. With 48 patents and a focus on pediatric orthopedics, OrthoPediatrics is dedicated to enhancing treatment options for children.